Repligen corporation

Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. Beforerepligen corporation, Repligen maintained dual capabilities in developing pharmaceutical therapeutics drug discovery and development and the development of materials supporting biological drug repligen corporation bioprocessing business. Repligen employs a direct sales model to users of its products in the United States, repligen corporation, with some sales through intermediaries in "certain foreign markets".

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in and is headquartered in Waltham, Massachusetts. Yahoo Finance.

Repligen corporation

Powered by. Repligen Corp Repligen is a life science company that develops and commercializes bioprocessing technologies for the manufacturing of biological drugs. Its products include upstream and downstream filtration, chromatography products, fluid management, cell culture supplements, ligands, and operating room disposables. The company also provides solutions to overcome the development and production of modalities into a new class of drugs. Its services comprise hands-on-process and implementation consultation services. Repligen is headquartered in Waltham, Massachusetts, the US. History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events. Have you found what you were looking for? Contact the team or request a demo to find out how our data can drive your business forward. Visit Corporate Site. Sign in. Book a demo. Industries We Cover Your curated industry news round-up. Subscribe now. Who We Serve Build your customized intelligence tool.

Authority control databases ISNI. Select Item. Traded as.

Overcome common challenges. Push the boundaries of what's possible. Maximize productivity at every step. Simplify complex workflows. Accelerate new modalities.

Tony J. Our order book strengthened by mid-quarter, delivering an overall book-to-bill of 1. In particular, orders from our Pharma customer base rebounded, with many of the projects highlighted on our second quarter call converting to purchase orders. In addition, we continued to see momentum in the gene therapy space and delivered another growth quarter for our Analytics business. Overall, we view the third quarter as an important transition period for the company and we are cautiously optimistic about the future in light of the strong finish on orders in the third quarter. Continued restructuring activities initiated in July to rebalance and streamline our operations and to support future margin expansion. Revenue detail. Totals may not add due to rounding.

Repligen corporation

With its stock down 4. Particularly, we will be paying attention to Repligen's ROE today. Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In simpler terms, it measures the profitability of a company in relation to shareholder's equity. Check out our latest analysis for Repligen. The 'return' is the amount earned after tax over the last twelve months.

Detailed lesson plan in science grade 8 pdf

Traded as. Repligen provides technology breakthroughs and scalable hardware, software and consumables workflow solutions for the development and manufacture of plasmid DNA, viral vectors, mRNA and new modalities such as whole cells, cultivated meat. Contact the team or request a demo to find out how our data can drive your business forward. Repligen Corp Repligen is a life science company that develops and commercializes bioprocessing technologies for the manufacturing of biological drugs. At the end of , Repligen out-licensed its spinal muscular atrophy program, in particular the small molecule candidate drug RG , to Pfizer. Push the boundaries of what's possible. The company was incorporated in and is headquartered in Waltham, Massachusetts. Repligen completes the acquisition of Metenova. Powered by. Official website. Repligen employs a direct sales model to users of its products in the United States, with some sales through intermediaries in "certain foreign markets". View Repligen Corp financials. Its products include upstream and downstream filtration, chromatography products, fluid management, cell culture supplements, ligands, and operating room disposables. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes.

Tony J. Strategically, we executed on two important deals, signing a year agreement with DRS Daylight Solutions on real-time process monitoring using mid-infrared technology and more recently extending our affinity ligand relationship with Purolite an EcoLab company until Our financial guidance for the fiscal year is based on expectations for our existing business and includes the financial impact of our acquisitions.

The PAT landscape in upstream intensification, the benefits of this approach, and the scale-up from benchtop to manufacturing is discussed. Tony J. Materials used in the manufacture of biological drugs. Repligen acquired Metenova, a leading Swedish innovator in magnetic mixing technology for biopharmaceutical production. Toggle limited content width. Authority control databases ISNI. Hidden categories: Articles with short description Short description is different from Wikidata Wikipedia articles in need of updating from August All Wikipedia articles in need of updating Articles containing potentially dated statements from All articles containing potentially dated statements Official website different in Wikidata and Wikipedia Articles with ISNI identifiers. Consultancy Custom Solutions. As a consequence of current operations, about one-third each of revenue and cost and expenses are denominated in Swedish krona currency, the remaining two-thirds denominated in United States dollars ; this presents a risk to the business based on unpredictable fluctuations in currency exchange rates. Save hours of research time and resources with our up-to-date Repligen Corp Strategy Report Understand Repligen Corp position in the market, performance and strategic initiatives. Key Financial Charts. Accelerate new modalities. Amounts are as of December 31, and compensation values are for the last fiscal year ending on that date. Contact the team or request a demo to find out how our data can drive your business forward.